Palvella Therapeutics, Inc.
QTORIN™ pitavastatin
disseminated superficial actinic porokeratosis
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for QTORIN™ pitavastatin in disseminated superficial actinic porokeratosis are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Phase 2 trial initiation expected in the second half of 2026”